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Neurodegeneration associated with amyloid β (Aβ) peptide accumulation, synaptic
loss, and memory impairment are pathophysiological features of Alzheimer’s disease
(AD). Numerous microRNAs regulate amyloid precursor protein (APP) expression and
metabolism. We previously reported that miR-101 is a negative regulator of APP
expression in cultured hippocampal neurons. In this study, a search for predicted APP
metabolism-associated miR-101 targets led to the identification of a conserved miR-101
binding site within the 3′ untranslated region (UTR) of the mRNA encoding Ran-binding
protein 9 (RanBP9). RanBP9 increases APP processing by β-amyloid converting enzyme 1
(BACE1), secretion of soluble APPβ (sAPPβ), and generation of Aβ. MiR-101 significantly
reduced reporter gene expression when co-transfected with a RanBP9 3′-UTR reporter
construct, while site-directed mutagenesis of the predicted miR-101 target site eliminated
the reporter response. To investigate the effect of stable inhibition of miR-101 both
in vitro and in vivo, a microRNA sponge was developed to bind miR-101 and derepress
its targets. Four tandem bulged miR-101 responsive elements (REs), located downstream
of the enhanced green fluorescence protein (EGFP) open reading frame and driven by the
synapsin promoter, were placed in a lentiviral vector to create the pLSyn-miR-101 sponge.
Delivery of the sponge to primary hippocampal neurons significantly increased both APP
and RanBP9 expression, as well as sAPPβ levels in the conditioned medium. Importantly,
silencing of endogenous RanBP9 reduced sAPPβ levels in miR-101 sponge-containing
hippocampal cultures, indicating that miR-101 inhibition may increase amyloidogenic
processing of APP by RanBP9. Lastly, the impact of miR-101 on its targets was
demonstrated in vivo by intrahippocampal injection of the pLSyn-miR-101 sponge into
C57BL6 mice. This study thus provides the basis for studying the consequences of
long-term miR-101 inhibition on the pathology of AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative dis-
order characterized by extracellular senile plaques, intracellular
neurofibrillary tangles (Krstic and Knuesel, 2013), and memory
loss. Increased amyloidogenic processing of amyloid precursor
protein (APP), a type I transmembrane protein, and accumu-
lation of its amyloid β (Aβ) peptide product have important
implications for AD pathogenesis. The Aβ peptide is derived from
the processing of APP through sequential cleavages by β and γ
secretases (Nalivaeva and Turner, 2013). Cleavage by β secre-
tase generates a large soluble fragment sAPPβ and a membrane
anchored C-terminal fragment, CTFβ; the latter may be further
cleaved by the γ-secretase complex and release Aβ as well as the
APP intracellular domain AICD. The Aβ load during disease pro-
gression is thought to lead to neurological dysfunction (reviewed
in Mucke and Selkoe, 2012).
The APP gene is linked to AD, and familial AD can be caused
by increased expression of APP (and consequently Aβ) due to
either genomic duplication or regulatory sequence alterations
(Podlisny et al., 1987; Rovelet-Lecrux et al., 2006; Theuns et al.,
2006).
RanBP9 interacts with APP and influences its trafficking
and processing (Lakshmana et al., 2009). RanBP9 is a scaffold-
ing protein involved in the modulation of neuronal functions
for the maintenance of cell homeostasis (Suresh et al., 2012).
RanBP9 interacts with low-density lipoprotein-related protein
(LRP), APP, and BACE1, promoting BACE1-dependent cleavage
of APP and Aβ generation both in vitro and in vivo (Lakshmana
et al., 2009, 2012). Furthermore, RanBP9 is increased in mutant
APP transgenic mice and in the degenerating brains of patients
with AD (Lakshmana et al., 2010, 2012). In addition, RanBP9
overexpression promotes neuronal apoptosis and potentiates Aβ-
induced neurotoxicity independently of its capacity to stimulate
Aβ generation (Woo et al., 2012), whereas RanBP9 transgenic
mice show a significantly increased incidence of synapse loss,
neurodegeneration, and spatial memory deficits (Lakshmana
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et al., 2012; Woo et al., 2012). These various actions of RanBP9
may contribute to the pathogenesis of AD.
The microRNAs represent an emerging class of small non-
coding RNAmolecules which, in mammals, regulate gene expres-
sion primarily by imperfect base pairing with the 3′-untranslated
region (UTR) of specific target mRNAs. Hence, microRNAs
mediate post-transcriptional repression of target mRNAs (Sun
and Lai, 2013). Changes of microRNA expression have been
shown to be associated to AD (Tan et al., 2013) and to be dereg-
ulated in transgenic animal models of AD (Lee et al., 2012;
Barak et al., 2013). MicroRNAs are among the molecules iden-
tified as physiological and pathological regulators of key genes
involved in AD, including APP (Patel et al., 2008; Hebert
et al., 2009; Liu et al., 2010; Vilardo et al., 2010; Long and
Lahiri, 2011; Smith et al., 2011; Long et al., 2012; Liang
et al., 2012), BACE1 (Hébert et al., 2008; Wang et al.,
2008; Boissonneault et al., 2009; Fang et al., 2012; Zhu
et al., 2012) and microtubule associated protein tau, MAPT
(Hébert et al., 2010). Each microRNA has the potential to
target a large number of mRNAs (Friedman et al., 2009)
and miRNAs may reinforce their effect through the simulta-
neous and coherent regulation of multiple targets (reviewed
in Inui et al., 2010). Indeed miRNAs that simultaneously
regulate APP/BACE1 expression have recently been described
(Fang et al., 2012; Ai et al., 2013).
Previously, we demonstrated that the 3′UTR of APP mRNA
can functionally interact with miR-101, a brain-enriched
microRNA, and that inhibition of endogenous miR-101 increases
APP levels. On the other hand, lentivirus-mediated overexpres-
sion of miR-101 significantly reduced APP expression and the Aβ
load in hippocampal neurons (Vilardo et al., 2010). Furthermore,
miR-101 is downregulated in the human AD brain, suggesting
that miR-101 expression levels may critically participate in the
pathogenesis of AD (Hébert et al., 2008; Nunez-Iglesias et al.,
2010).
Here searching for predicted APPmetabolism-associated miR-
101 targets we further investigated the action of endogenous miR-
101 in hippocampal neurons. The hippocampus is affected during
the early stages of AD, and changes in the hippocampus coin-
cide with thememory deficits observed in AD patients. Therefore,
study of hippocampal cells may improve our understanding of
the role of miR-101 and other microRNAs in the gene regulation
as well as the involvement of microRNAs in neurodegenerative
processes associated with the progression of AD.
Our study provides evidence that miR-101 may regulate not
only APP but also RanBP9 in hippocampal neurons both in vitro
and in vivo and that miR-101-mediated post-transcriptional reg-
ulation of RanBP9 may modulate the amyloidogenic processing
of APP.
MATERIALS AND METHODS
CELL CULTURE
Primary hippocampal neurons were prepared from day 17–18
embryos obtained from timed-pregnant Wistar rats (Charles
River). Neurons were plated at a density of 1 × 106 cells/dish
on 3.5-cm tissue culture dishes pre-coated with poly(D/L-lysine)
and cultured in neurobasal medium supplemented with B-27 and
GlutaMAX™ (Gibco). Half of the mediumwas changed every 3–4
days. The neurons were transduced at 7 days in vitro with 2 × 106
transducing units (TU)/mL of the pLSyn-miR-101 sponge vector
(constructed as described below), or with a control pLSyn vec-
tor expressing only EGFP. Protein lysates were collected at 7 days
post-transduction and used in Western blotting experiments, as
described below.
SH-SY5Y neuroblastoma cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine
serum in a 5% CO2-humidified incubator at 37◦C. The cells were
used in luciferase assays, as described below.
LUCIFERASE REPORTER GENE CONSTRUCTS AND LUCIFERASE ASSAY
The SC-RANBP9 3′UTR was purchased from Origene
(SC210772). The SC control firefly vector was derived from
the SC-RANBP9 3′UTR. The RANBP9 luciferase mutant con-
structs were generated by using the QuikChange® II Site-Directed
Mutagenesis Kit (Stratagene) and the following synthetic oligonu-
cleotides: RanBP9 3′UTRmut up, 5′-ATGGAAGAAATCATTTTT
AATGTGTAGAGTAAAACTTGAAATACTCAGGAGCTG-3′; and
RanBP9 3′UTR mut down, 5′-CAGCTCCTGAGTATTTCAAGTT
TTACTCTACACATTAAAAATGATTTCTTCCAT-3′.
SH-SY5Y cells were plated at a density of 0.6 × 105 per
well in 24-well plates and transfected after 24 h with 20 pmole
of the indicated microRNA duplexes (Dharmacon) and 50 ng
of the firefly luciferase expression vector conjugated to 0.5μL
Lipofectamine 2000 (Invitrogen) in Opti-MEM® reduced-serum
medium (Gibco). Cells were lysed at 24 h after transfection, and
luciferase assays were performed by using the Dual Luciferase
Reporter Assay System (Promega) according to the manufac-
turer’s protocol. The experiments were carried out in triplicate.
PREPARATION OF THE miR-101 SPONGE, miRNA AND SILENCING RNA
LENTIVIRAL VECTORS, AND VIRAL PARTICLES
The pLSyn vector was described previously (Barbato et al., 2010).
The miR-101 sponge was constructed by using the following
synthetic oligonucleotides: S1 CATAATTCAGTTATCCAGTACT
GTACGATTTCAGTTATCCAGTACTGTAACCGGT; AS1 TACA
GTACTGGATAACTGAAATCGTACAGTACTGGATAACTGAAT
TATGGTAC; S2 TT CAGTTATCCAGTACTGTATCACTTCAG
TTATCCAGTACTGTACCCGGGGGTACCGAGCT; and AS2 CG
GTACCCCCGGGTACAGTACTGGATAACTGAAGTGATACAG
TACTGGATAACTGAAACCGG. Oligonucleotides S1 and S2,
containing four tandem bulged miR-101 binding sites (at
position 11), were annealed with AS1 and AS2, respectively,
ligated, and digested with the KpnI restriction enzyme. The
product was purified and cloned into the KpnI site of the
pLSyn backbone, downstream of the woodchuck hepatitis virus
post-transcriptional regulatory element. PLB-scr and pLB-101
lentiviral vector have been previously described (Vilardo et al.,
2010).
RanBP9 downregulation was induced by using a lentiviral
vector expressing a silencing (si) RNA that targets rat RanBP9
mRNA (sh-RanBP9, TRCN0000102112, Sigma-Aldrich), and a
control vector expressing a siRNA that does not target rat mRNAs
(SHC002, Sigma-Aldrich).
The preparation of the G glycoprotein vesicular stomati-
tis virus-pseudotyped lentiviral particles has been described
previously (Barbato et al., 2010). Briefly, HEK293T cells were
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transduced with viral vectors, and the virus-containing medium
was harvested 60 h later, filtered through a 0.45-mm Durapore
Stericup unit, and concentrated by a two-step ultracentrifugation
procedure. The titers of the viral vectors used in this study were
in the range of 1–3 × 109 TU/ml.
ANIMALS
A total of 12 males C57BL/6Ncrl mice (Charles River, Italy) were
used at the age of 6–7 weeks. All experiments were performed
in accordance with European Community Directive 86/609/EC.
Mice were unilaterally microinfused into the CA1 field of the hip-
pocampus with lentiviral particles derived from the control pLSyn
vector (n = 6) or the pLSyn-miR-101 sponge vector (n = 6), as
described below.
INTRAHIPPOCAMPAL INJECTION OF LENTIVIRAL VECTORS
Mice were anesthetized with chloral hydrate (400mg/kg,
i.p.). Holes were drilled above the CA1 field of the hip-
pocampus (anterior/posterior = −2.2, medial/lateral = ±1.8,
ventral = −1.8) by using standard stereotaxic procedures.
Control pLSyn vector or pLSyn-miR-101 sponge vector (1μL)
was unilaterally microinfused into the hippocampus via a stain-
less steel cannula (0.1mm in diameter) connected to a Hamilton
microsyringe. An infusion pump was maintained at an infusion
rate of 0.2μL/min, and the cannula was left in place for 5min
following completion of the infusion. Two weeks later, the hip-
pocampi were removed and processed for subsequent analyses, as
described below.
RNA EXTRACTION AND ANALYSIS
Total RNA was extracted from primary hippocampal neurons
with TRIzol (Invitrogen) according to themanufacturer’s instruc-
tions. RNA quantitation was performed via quantitative real-time
PCR (RT-PCR). The total RNA was treated using the TURBO
DNA-free™ Kit (Ambion), reverse-transcribed with SuperScript
III reverse transcriptase (Invitrogen), and amplified by using the
SensiMixPlus SYBR Kit (BioLine) and the 7900HT Fast Real-
Time PCR System (Applied Biosystems). Oligonucleotides ampli-
fying the TATA binding protein (TBP), APP, and RanBP9 were
chosen from the Roche Universal Probe Library and were as
follows:
rno-TBP-1029-1048FW CCCACCAGCAGTTCAGTAGC
rno-TBP-1081-1103RW CAATTCTGGGTTTGATCATTCTG
rno-APP-FW GCCTGAACTCGAATTAATATACA
rno-APP-RW GCTTCTTCTTCCTCAACATCG
rno-Ranbp9-675-693 FW TGCTTTCACCGACTTACCG
rno-Ranbp9-737-755 RW CCAAAGTTGGCATCAACCA
Relative changes in gene expression were quantified by apply-
ing the comparative threshold method (Ct) after determining the
Ct values for the reference gene (TBP, the endogenous control)
and the target genes in each sample set according to the 2−Ct
method. All reactions were performed in triplicate.
PROTEIN EXTRACTION ANDWESTERN BLOT ANALYSIS
Hippocampal tissues or cultured cells were homogenized in buffer
(1% Triton, 0.25% sodium dodecyl sulphate (SDS), 1% sodium
deoxycholate, 2mM EDTA, and 1mM dithiothreitol) supple-
mented with a protease inhibitor mixture (Sigma-Aldrich) to
yield total protein extracts. The standard 2X Laemmli load-
ing buffer contained 4% SDS, 10% β-mercaptoethanol, 20%
glycerol, and 0.04% bromophenol blue in 125mM Tris-HCl,
pH 6.8. Equal amounts of total protein extract were fraction-
ated by electrophoresis in an 8% SDS-polyacrylamide gel and
then transferred to a nitrocellulose membrane (Hybond-ECL,
GE Healthcare). Membranes were incubated with the indi-
cated primary antibody overnight at 4◦C. Incubation with a
secondary peroxidase-coupled anti-mouse or anti-rabbit anti-
body (GE Healthcare) was performed at room temperature for
1 h. Immunoreactivity was determined by using an enhanced
chemiluminescence detection kit (Millipore). The following pri-
mary antibodies and dilutions were used: mouse monoclonal
anti-APP (4G8, 1:500, Signet), rabbit polyclonal anti-sAPPβ
(SIG-39138, 1:1000, Covance), rabbit polyclonal anti-RanBP9
(ab78127, 1:2000, Abcam), mouse monoclonal anti-GFP (1:2000,
JL-8 632380 Clontech) and anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (1:6000, Covance).
RESULTS
RanBP9 IS A TARGET OF miR-101
To identify putative miR-101 target mRNAs associated with APP
metabolism, we used several microRNA target prediction com-
putational programs, such as TargetScan, Pictar, and miRanda
(Gomes et al., 2013). Some features of these target prediction
programs are: the ability to predict base-pairing patterns and the
thermodynamic stability of microRNA-mRNA hybrids, as well as
the capacity to perform comparative sequence analysis to evaluate
sequence conservation and the individuation of multiple target
sites.
Our analysis revealed a putative miR-101 RE within the 3′UTR
of the mRNA encoding RanBP9 (seed location 507–513 bp),
which is conserved among vertebrates (Figure 1A). The RanBP9
protein interacts with the cytoplasmic tails of LRP, APP and
BACE1 proteins promoting BACE1-dependent cleavage of APP
and Aβ generation both in vitro and in vivo (Lakshmana et al.,
2009, 2012). To determine whether the RanBP9 gene is a target
of miR-101, we introduced a firefly reporter vector contain-
ing the full-length RanBP9 3′UTR (883 bp) downstream of the
luciferase open reading frame into SH-SY5Y neuroblastoma cells.
SH-SY5Y cells were co-transfected with either a reporter con-
struct containing the RanBP9 3′UTR or with a control firefly
plasmid, in addition to a synthetic miR-101 precursor or a con-
trol microRNA (Figures 1B,C). The synthetic miR-101 precursor
significantly reduced luciferase expression by more than 40% rel-
ative to the control microRNA. The repressive effect of miR-101
on the RanBP9 3′UTR was abrogated by site-directed mutagen-
esis of the nucleotides at positions 4 and 5 of the miR-101 RE at
507–513 bp. These data indicate that miR-101 negatively regulates
RanBP9 expression.
A LENTIVIRAL SPONGE INDUCES THE EXPRESSION OF miR-101
TARGETS IN HIPPOCAMPAL NEURONS
To assay the effects of miR-101 on its target genes and their
protein products in hippocampal neurons, we used a lentiviral
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FIGURE 1 | The conserved miR-101 target site at the 507–513bp region
of the RanBP9 3′UTR is necessary for RanBP9 post-transcriptional
regulation. (A) Ribonucleotide sequences of the conserved putative
miR-101 RE within the RanBP9 3′UTR paired with the mature miR-101
sequence. (B) Schematic representation of the luciferase constructs used in
this study. The miR-101 RE within the RanBP9 3′-UTR is underlined. In the
mutant construct, the nucleotides at positions 4 and 5 of the miR-101 RE
were mutated, as indicated in bold font. (C) SH-SY5Y neuroblastoma cells
were transfected independently with the SC control plasmid or with each of
two SC-RanBP9 luciferase reporter genes together with either miR-101 or a
control microRNA (cel-miR-67) (100 nM). At 24 h post-transfection,
luciferase activity was determined. Results are presented as the normalized
activity of miR-101-transfected cells relative to that of cells transfected with
cel-miR-67. Data are presented as the means ± the SE from three or four
independent experiments (∗∗p < 0.01, Student’s t-test).
pLSyn-miR-101 sponge vector in which the synapsin promoter
controlled the expression of four tandem bulged miR-101 REs
located downstream of the EGFP open reading frame (Figure 2).
Rat hippocampal cultures were transduced at 7 days in vitro with
either the control pLSyn vector or the pLSyn-miR-101 sponge
vector. Seven days later, the lentiviral vector-transduced hip-
pocampal neurons expressed EGFP mRNA at a sub-saturating
level, resulting in a notable reduction in EGFP fluorescence in
the pLSyn-miR-101 sponge-containing neurons vs. the pLSyn
vector-containing neurons (Figure 2).
We next evaluated the capacity of the miR-101 sponge to affect
miR-101-mediated post-transcriptional regulation by measuring
FIGURE 2 | Expression of the pLSyn-miR-101 sponge in primary
hippocampal neurons. A schematic representation of the pLSyn-miR-101
sponge and the control pLSyn lentiviral vector is shown. The EGFP signal
was slightly lower in the pLSyn-miR-101 sponge-containing neurons (top
image) at 14 days post-transduction with respect to the pLSyn-containing
neurons (bottom image). Left: phase contrast images, right: EGFP signal.
the protein expression levels of APP and RanBP9 in primary
hippocampal neurons transduced with either the pLSyn-miR-
101 sponge vector or the control pLSyn vector. Western blot-
ting analysis showed that APP and RanBP9 proteins levels were
significantly increased in neurons transduced with the pLSyn-
miR-101 sponge vector compared with the control pLSyn vector
(Figures 3A,B). However, no significant alterations in APP or
RANBP9 mRNA levels were observed (Figure 3C). These results
suggest that the increase in APP and RanBP9 expression is likely
due to a relief of microRNA-mediated translational suppression.
Consistently with these data we found that the over-expression of
miR-101 in hippocampal neurons induced a significant downreg-
ulation of RanBP9 protein (Figure S2).
Because RanBP9 increases the amyloidogenic processing
of APP to yield sAPPβ by modulation of BACE1 activity
(Lakshmana et al., 2009), sAPPβ levels in the extracellular
medium of lentiviral vector-transduced hippocampal neurons
were next examined. The secretion of sAPPβ into the condi-
tioned culture medium was significantly increased for neurons
transduced with the pLSyn-miR-101 sponge vector relative to the
control pLSyn vector (Figure 3D). This result demonstrates that
the inhibition of miR-101 action on its target genes increases the
amyloidogenic processing of APP.
SILENCING OF RanBP9 AFTER miR-101 INHIBITION MITIGATES sAPPβ
OVERPRODUCTION
To evaluate the role of RanBP9 in sAPPβ overproduction, we ana-
lyzed the levels of sAPPβ in pLSyn-miR-101 sponge-containing
hippocampal cultures in which RanBP9 was downregulated.
Cultured hippocampal neurons expressing the miR-101 sponge
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FIGURE 3 | Inhibition of miR-101 in neurons increases levels of
endogenous RanBP9, full-length APP, and its secreted product,
sAPPβ. (A) Representative Western blot analysis of protein extracts from
lentiviral vector-transduced hippocampal neurons at 7 days post-infection
with an antibody recognizing RanBP9, an antibody recognizing full-length
APP (4G8), or an antibody recognizing GAPDH. Full blot for RanBP9 with
multiple samples is shown in Figure S1. (B) The intensities of the bands
were quantified by densitometry. The results obtained with the 4G8
antibody or the RanBP9 antibody were normalized to those obtained with
the GAPDH antibody and expressed as arbitrary optical density (OD)
units. The band intensities for miR-101 sponge-containing neurons were
quantified relative to those for control pLSyn vector-containing neurons.
(C) Quantitative RT-PCR for APP and RanBP9 mRNA, using hippocampal
cell total RNA as the template. Expression levels in miR-101
sponge-transduced neurons relative to control pLSyn vector-transduced
cells are shown. (D) Conditioned culture medium samples from
lentivirus-transduced hippocampal neurons were collected from cells
cultured in 35-mm dishes, normalized according to the protein content of
the corresponding cell extracts, and analyzed by Western blotting with
the sAPPβ antibody, which recognizes the secreted form of APP. Cultures
expressing the pLSyn-miR-101 sponge exhibited sAPPβ levels that were
1.3-fold higher than the control levels found in pLSyn-transduced cells.
Results in (B–D) are presented as the means ± the SE of three
independent experiments (∗p < 0.05, Student’s t-test).
were transduced with a lentiviral vector containing RanBP9
siRNA under the control of the U6 promoter, or with a control
lentiviral vector expressing a scrambled siRNA. The pLSyn
vector-containing hippocampal neurons transduced with the
scrambled lentiviral vector were used as the experimental control.
Neurons were collected at 96 h after RanBP9 silencing and
subjected to Western blot analysis for APP, RanBP9, and sAPPβ
(Figure 4). The pLSyn-miR-101 sponge-containing neurons
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FIGURE 4 | Silencing of RanBP9 reverses oversecretion of sAPPβ into
the conditioned medium of pLSyn-miR-101-containing hippocampal
neurons. Hippocampal neurons at 7 days in vitro were infected with the
control pLSyn vector or the pLSyn-miR-101 sponge vector. Seventy-two
hours later, the cells were transduced with a lentiviral vector containing
RanBP9 siRNA under the control of the U6 promoter, or with a control
lentivirus expressing a scrambled siRNA. After 14 days, the neurons
were collected for Western blot analysis. (A) Representative immunoblots
of protein extracts from lentiviral vector-transduced neurons reacted with
an antibody recognizing RanBP9, an antibody recognizing full-length APP
(4G8), or an antibody recognizing GAPDH are shown. Alternatively,
conditioned culture medium samples were collected from lentiviral
vector-transduced hippocampal neurons cultured in 35-mm dishes,
normalized according to the protein content of the corresponding cell
extracts, and analyzed by Western blotting with the sAPPβ antibody. (B)
Quantitative data are provided in the histogram. The data are expressed
as means ± the SE of three independent experiments (∗p < 0.05,
Student’s t-test).
transduced with the scrambled siRNA showed an increase in
all three proteins compared with the control neurons. On the
other hand, the pLSyn-miR-101 sponge-containing neurons with
silenced RanBP9 showed a positive correlation between decreased
RanBP9 expression and attenuated sAPPβ secretion into the
conditioned medium (Figure 4). This observation suggests that
RanBP9 upregulation may increase sAPPβ production when
miR-101 is inhibited.
THE miR-101 SPONGE INDUCES APP AND RanBP9 EXPRESSION
IN VIVO
The significance of miR-101-mediated post-transcriptional reg-
ulation on the expression of its targets was evaluated in vivo by
unilaterally injecting lentiviral particles into the hippocampus
of adult mice. Infection was monitored by western blot anal-
ysis of EGFP expression. Two weeks after injection, the right
and left sides of the hippocampus were processed for biochem-
ical analysis. Western blotting showed that the expression of
the miR-101 sponge induced the upregulation of the APP and
RanBP9 proteins in the injected side of the hippocampus rel-
ative to the non-injected side (Figure 5). The injection of the
control lentivirus did not appreciably alter the expression of
either miR-101 target (Figure 5). These findings indicate that
miR-101-mediated post-transcriptional regulation is involved
in the APP metabolism of adult neurons both in vivo and
in vitro.
DISCUSSION
MicroRNAs are abundantly expressed in the brain, where they
play important roles in neural development and function.
MicroRNAs also feature predominantly in gene regulation under
both normal and pathological conditions (Eacker et al., 2013).
Changes in microRNA expression are found in the brains of
patients affected by various neurological diseases, including AD.
Several in vitro and in vivo studies explored the functional role of
microRNAs in AD pathogenesis, and showed that these molecules
are potentially involved in the regulation of APP metabolism
(reviewed in Delay et al., 2012). Notably, aberrant processing of
APP is implicated as a causative factor in AD (Nalivaeva and
Turner, 2013).
Recently, we reported that miR-101 is among the microRNA
species that target the APP gene (Vilardo et al., 2010). In addi-
tion, miR-101 is also downregulated in the human AD cerebral
cortex (Hébert et al., 2008; Nunez-Iglesias et al., 2010). Here, we
demonstrate that the RanBP9 gene is a novel target of miR-101,
and that miR-101 is involved in the amyloidogenic processing
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FIGURE 5 | Full-length APP and RanBP9 are targets of miR-101 in
mouse hippocampal neurons in vivo. Western blotting was performed of
hippocampal tissues injected and non-injected with lentiviral vectors.
Effective expression of the lentiviral vector was revealed by the presence of
EGFP (data not shown). Expression of the miR-101 lentiviral sponge
resulted in an increase in the protein expression levels of the miR-101
targets, APP and RanBP9, with respect to non-injected tissue. APP and
RanBP9 band intensities were quantified by densitometry, normalized to
the GAPDH signal, and expressed as arbitrary OD units. The relative ratio of
APP (pLSyn n = 3; pLSyn-miR-101 sponge n = 4) and RanBP9 (pLSyn n = 3;
pLSyn-miR-101 sponge n = 4) expression in injected vs. non-injected tissue
is shown. Results are presented as the means ± the SE (∗p < 0.05;
∗∗p < 0.01, Student’s t-test).
of APP by downregulating the expression of the RanBP9 pro-
tein. RanBP9 regulates Aβ peptide production in several cell lines
and primary neuronal cultures and exerts its actions by form-
ing protein complexes with APP, LRP, and BACE1, leading to the
increased proteolytic processing of APP, secretion of sAPPβ, and
generation of Aβ, which is present in excessive amounts in the
brains of AD patients. Through the use of computational predic-
tion programs, we found a putative conserved miR-101 RE within
the RanBP9 mRNA 3′UTR. Furthermore, luciferase assays and
site-directed mutagenesis experiments demonstrated a functional
interaction between the RanBP9 3′UTR and miR-101.
It is worth mentioning that beyond miR-101, among several
microRNAs reported to regulate APP expression, miR-153 (Long
et al., 2012) is also predicted to target human and mouse, but
not rat, RanBP9 3′UTR. However, the miR-153 binding site is
very close to the RanBP9 open reading frame suggesting that the
efficiency of targeting should be low (Grimson et al., 2007).
Next, we demonstrated the specific relevance of miR-101-
mediated post-transcriptional regulation of the RanBP9 gene to
APP metabolism in hippocampal neurons. We first took advan-
tage of the neuron-selective synapsin promoter (Kügler et al.,
2003) to express a lentiviral miR-101 sponge in cultured neu-
rons. This sponge interferes with the actions of miR-101 on its
targets, including the RanBP9 gene. Inhibition of miR-101 via
delivery of the sponge increased protein expression levels of APP
and RanBP9, as well as the secretion of sAPPβ. Moreover, the
overproduction of sAPPβ in the extracellular medium of pLSyn-
miR-101 sponge-containing neurons was reversed by RanBP9
silencing. Intrahippocampal injection of lentiviral sponge parti-
cles in adult mice also demonstrated that the APP and RanBP9
genes are regulated by miR-101 in adult hippocampal neurons
in vivo.
Our data indicate that RanBP9 translation may be mod-
ulated by microRNA post-transcriptional regulation. On the
other hand a recent study suggests that additional pathways
may regulate RanBP9 protein expression (Wang et al., 2013).
Indeed RanBP9 protein half-life is increased by COPS5, a
novel RanBP9-interacting protein that increases the stability of
its interacting proteins most likely through an action on the
ubiquitin-proteosome system (Wang et al., 2013).
APP expression is extensively regulated at post-transcriptional
level by several microRNAs and different RNA binding proteins
(reviewed by Ruberti et al., 2010). To date, however, interac-
tions between these regulatory mechanisms on APP expression
have not been evidenced. The Fragile X Mental Retardation
Protein (FMRP) binds APP mRNA and represses its translation
(Westmark and Malter, 2007). Interestingly RanBP9 may interact
with FMRP and inhibit its RNA binding activity (Menon et al.,
2004). It would therefore be tempting to speculate that APP pro-
tein levels may be influenced by miR-101 post-transcriptional
regulation of FMRP/RanBP9 complex. Since RANBP9 silencing
in pLSyn-miR-101 sponge neurons did not reverse APP protein
overexpression we can exclude that RANBP9 protein levels were
indirectly modulating APP translation.
Our data showed that miR-101 regulates two target genes
that are closely associated with AD, Further investigations are
required to determine whether alteration of this regulatory mech-
anism may affect AD pathogenesis. Importantly, experimental
evidence suggests that if the amyloidogenic processing of APP
could be halted or decelerated, the devastating effects of AD
might be mitigated. Thus, the elucidation of which microRNAs
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act on APP metabolism provides researchers with a specific
focus for the development of new drugs for the management
of AD. Furthermore, the demonstration that RanBP9 is post-
transcriptionally regulated by miR-101 might have interesting
disease implications independently of its effects on amyloidogenic
processing, because the overexpression of RanBP9 can induce
neuronal apoptosis without generating Aβ peptides (Woo et al.,
2012), and RanBP9 transgenic mice show synapse loss, neurode-
generation, and spatial memory deficits (Lakshmana et al., 2012;
Woo et al., 2012).
Finally, miR-101 is downregulated in the hippocampus of very
old vs. young wild-type mice, and in both very old and young
mouse models of AD compared with their age-matched normal
controls (Barak et al., 2013). Further studies in mouse models
may therefore elucidate the consequences of long-term inhibition
of miR-101 on AD pathology.
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Figure S1 | The gel blot of RanBP9 protein level in three independent
hippocampal cultured neurons expressing the miR-101 sponge construct
(pLSyn-miR-101 sponge) and the parental control vector (pLSyn). Two
exposure time of RanBP9 are shown.
Figure S2 | Reduction of RanBP9 protein levels by miR-101 overexpression.
(A) Western immunoblots show the expression of RanBP9 and APP in
hippocampal neurons that were transduced with either a control lentiviral
vector (pLB-scr) expressing a control microRNA or a lentiviral vector
expressing a mature miR-101 (pLB-101) (B) GAPDH-relative expressions
are shown in the histogram. Data are presented as the means ± the SD
(∗p < 0.05; ∗∗p < 0.01, Student’s t-test; n = 3).
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